Patents by Inventor Elazar Rabbani

Elazar Rabbani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine pathway modulating compounds for the treatment of coronavirus infection
    Patent number: 11931344
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: March 19, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS
    Publication number: 20240024259
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: July 28, 2023
    Publication date: January 25, 2024
    Applicant: ENZO BIOCHEM, INC.
    Inventors: Elazar RABBANI, James J. DONEGAN
  • Assays for detecting modified compounds
    Patent number: 11874281
    Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: January 16, 2024
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Joshua Rabbani, Praveen Pande
  • Sphingosine pathway modulating compounds for the treatment of cancers
    Patent number: 11865105
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 9, 2024
    Assignee: ENZO BIOCHEM, INC.
    Inventors: Elazar Rabbani, James J. Donegan
  • Compositions for Preparing Regulatory T-Cell Compositions for the Treatment of Autoimmune Disease
    Publication number: 20230364145
    Abstract: The invention provides cell culture compositions for regulatory T-cells that include particular synthetic peptides. Also provided are methods of treating autoimmune diseases such as age-related macular degeneration and uveitis with regulatory T-cells prepared using said compositions.
    Type: Application
    Filed: July 26, 2023
    Publication date: November 16, 2023
    Applicant: ENZO BIOCHEM, INC.
    Inventors: Robert NUSSENBLATT, Baoying LIU, Lai WEI, Elazar RABBANI, James J. DONEGAN
  • Reduced background immunoassay plates
    Patent number: 11745184
    Abstract: The invention provides reduced background substrates, such as multi-well plates, for use in enzyme-linked immunosorbent assays (ELISAs) and other ligand-binding assays, and methods for making and using the same.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: September 5, 2023
    Inventor: Elazar Rabbani
  • Sphingosine pathway modulating compounds for the treatment of coronavirus infection
    Patent number: 11723895
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: August 15, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection
    Publication number: 20230158003
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: January 11, 2023
    Publication date: May 25, 2023
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Sphingosine pathway modulating compounds for the treatment of coronavirus infection
    Patent number: 11554111
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 17, 2023
    Assignee: ENZO BIOCHEM, INC.
    Inventor: Elazar Rabbani
  • USE OF ORGANIC CATIONIC COMPOUNDS TO ACCELERATE NUCLEIC ACID HYBRIDIZATION, SYNTHESIS, AND AMPLIFICATION
    Publication number: 20230002805
    Abstract: The invention provides methods for accelerated synthesis of nucleic acids, and related compositions which involve the use of organic amines in the nucleic acid synthesis reaction mixture. The invention also provides methods for reducing processing steps associated with nucleic acid synthesis. The invention further provides methods for screening compounds that have positive benefits on the synthesis of nucleic acids.
    Type: Application
    Filed: December 15, 2021
    Publication date: January 5, 2023
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jack Coleman
  • ASSAYS FOR DETECTING MODIFIED COMPOUNDS
    Publication number: 20220034897
    Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 3, 2022
    Applicant: Enzo Life Sciences, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Joshua Rabbani, Praveen Pande
  • Fluorescence Quencher Polymer Conjugates and Uses Thereof
    Publication number: 20220025188
    Abstract: The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.
    Type: Application
    Filed: June 30, 2021
    Publication date: January 27, 2022
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jack Coleman
  • IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNTHETIC PEPTIDE AND TRANSFORMING GROWTH FACTOR BETA
    Publication number: 20220023402
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Applicant: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • Assays for detecting modified compounds
    Patent number: 11181528
    Abstract: Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified. The modifications may take the form of functional groups which are gained, lost or retained by the compounds of interest.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 23, 2021
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, Joshua Rabbani, Praveen Pande
  • Immunomodulatory pharmaceutical compositions including a synthetic peptide and transforming growth factor beta
    Patent number: 11173195
    Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-?).
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
  • COMPREHENSIVE AND COMPARATIVE FLOW CYTOMETRY-BASED METHODS FOR IDENTIFYING THE STATE OF A BIOLOGICAL SYSTEM
    Publication number: 20210301357
    Abstract: The invention provides comprehensive and comparative flow cytometry-based methods for characterizing the state of a biological system by determining cell phenotypes and associated gene expression profiles.
    Type: Application
    Filed: May 4, 2021
    Publication date: September 30, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan, Andrew Stewart L'Huillier
  • Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus Infection
    Publication number: 20210290600
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS INFECTION
    Publication number: 20210290567
    Abstract: The invention provides methods and compositions for treating a coronavirus infection using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 23, 2021
    Applicant: Enzo Biochem, Inc.
    Inventor: Elazar Rabbani
  • Affinity tag nucleic acid and protein compositions, and processes for using same
    Patent number: 11066694
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 20, 2021
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo
  • AFFINITY TAG NUCLEIC ACID AND PROTEIN COMPOSITIONS AND PROCESSES FOR USING SAME
    Publication number: 20210214767
    Abstract: The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, Jannis G. Stavrianopoulos, James J. Donegan, Wayne Patton, Juan Carcamo, Jack Coleman